Novel Anti-Inflammatory Properties of Breast Milk in Necrotizing Enterocolitis
Novel Anti-Inflammatory Properties of Breast Milk in Necrotizing Enterocolitis
批准号:
9418041
负责人:
MISTY L GOOD
金额:
$14.63万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-15 至 2018-08-31
关键词:
AddressAdvisory CommitteesAffectAnti-Inflammatory AgentsAnti-inflammatoryAttenuatedCD14 AntigenCell Differentiation processCell ProliferationCell physiologyCellsCellular biologyCessation of lifeClinicalComplexDataDevelopmentDevelopment PlansDiseaseDrug TargetingEducational ActivitiesEndotoxemiaEnterocytesEnvironmentEpidermal Growth FactorEpidermal Growth Factor ReceptorEpithelialEpithelial Cell ProliferationEpithelial CellsEtiologyGastrointestinal DiseasesGoalsGoblet CellsHumanHuman MilkImmunologyImpairmentIncidenceInfantInfant MortalityInflammationInflammatoryInflammatory ResponseInflammatory disease of the intestineInjuryIntestinesK-Series Research Career ProgramsKnowledgeLaboratoriesMediatingMentorsModelingMolecularMolecular BiologyMothersMucositisMusNF-kappa BNecrosisNecrotizing EnterocolitisOrgan failureOutcomePathogenesisPathologicPlayPopulationPremature InfantProcessPropertyProphylactic treatmentProtective AgentsResearch PersonnelRoleSeveritiesSignal PathwaySignal TransductionSignal Transduction PathwayStem cellsStructureSurvival RateSystemTLR4 geneTestingUnited StatesWNT Signaling PathwayWorkbasecareercareer developmentclinically relevantcytokinedesignfield studyhealinginhibitor/antagonistintestinal epitheliummeetingsmigrationmortalitynotch proteinnovelprotective effectpublic health relevancesuccesssymposiumtherapeutic developmenttherapeutic target
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This application is for a K08 Career Development Award investigating the novel anti-inflammatory properties of breast milk in necrotizing enterocolitis (NEC). NEC affects nearly 1 out of 10 premature infants weighing less than 1500 grams, with a mortality of up to 50%. It is characterized by intestinal barrier disruption and intestinal necrosis, multi-system organ failure and death. The specific molecular mechanisms responsible for the development of NEC remain unclear. Our laboratory has shown that activation of the bacterial lipopolysaccharide receptor, toll-like receptor 4 (TLR4) is required fo NEC development and that TLR4 activation leads to two key pathological features of NEC: NF-kB-mediated inflammatory response with associated intestinal injury and impaired mucosal healing. Breast milk is the only known protective agent against NEC, but the specific protective component and protective mechanism remain unknown. Our preliminary studies show breast milk decreases TLR4 signaling and a major factor mediating this protective effect is epidermal growth factor (EGF). The overall hypothesis is that activation of the EGF receptor ameliorates NEC by antagonizing at least two major deleterious aspects of TLR4 signaling: inflammation and impaired epithelial healing. The protection seen with EGFR activation likely involves the competitive interaction of several signal transduction pathways. Therefore, we further hypothesize that the EGF in breast milk promotes intestinal cell healing by enhancing Wnt and decreasing Notch activation. To test this hypothesis, we will use our experimental NEC model to pursue the following specific aims: 1. To determine the extent that breast milk inhibits TLR4-mediated inflammatory signaling in NEC. 2. To characterize the effects of breast milk on intestinal epithelial cell proliferation and mucosal healing. 3. To determine the mechanisms by which breast milk regulates intestinal epithelial cell differentiation via TLR4-mediated Notch activation in NEC pathogenesis. The candidate is a Neonatologist who has been working closely with her mentor for the past four years. She benefits from a well-established and successful mentor with a supportive academic environment. In addition, the candidate meets on a regular basis with her Scientific Advisory Committee, which is comprised of experts in Immunology, Cell Biology and Physiology, and her collaborator, Dr. Jennifer Grandis with expertise in EGFR signal transduction. The candidate's immediate goals are to gain increased knowledge in molecular biology, immunology and signal transduction. Her long-term career goals are to become a productive independent investigator who will significantly contribute to the field studying the pathogenesis of NEC. To achieve these goals, a structured career development plan was developed which includes: gaining knowledge through educational activities, course work, conferences, frequent mentor meetings with a gradual increase in independence and a Scientific Advisory Committee who is devoted to the candidate's success.
期刊论文(12)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.7554/elife.05477
发表时间:
2015-03-03
期刊:
eLife
影响因子:
7.7
作者:
[Raveh-Sadka T, Thomas BC, Singh A, Firek B, Brooks B, Castelle CJ, Sharon I, Baker R, Good M, Morowitz MJ, Banfield JF]
通讯作者:
Banfield JF
DOI:
10.1016/j.cyto.2017.06.017
发表时间:
2017-12
期刊:
Cytokine
影响因子:
3.8
作者:
[Hodzic Z, Schill EM, Bolock AM, Good M]
通讯作者:
Good M
Mid-Aortic Syndrome in a Preterm Infant: A Rare Cause of Hypertension.
早产儿的中主动脉综合征:高血压的罕见原因。
DOI:
10.1016/j.jpeds.2015.05.007
发表时间:
2015
期刊:
The Journal of pediatrics
影响因子:
--
作者:
[Harmon,CMiles, Azzuqa,AbeerA, Ranganathan,Sarangarajan, Mahmood,Burhan, Good,Misty]
通讯作者:
Good,Misty
DOI:
10.3390/nu7095383
发表时间:
2015-09-21
期刊:
Nutrients
影响因子:
5.9
作者:
[Barragan M, Good M, Kolls JK]
通讯作者:
Kolls JK
Editorial: Organogenesis: From Development to Disease.
社论:器官发生:从发育到疾病。
DOI:
10.3389/fcell.2017.00085
发表时间:
2017
期刊:
Frontiers in cell and developmental biology
影响因子:
5.5
作者:
[Sims-Lucas,Sunder, Good,Misty, Vainio,SeppoJ]
通讯作者:
Vainio,SeppoJ
共 7 条
Neonatal gut-on-a-chip platform for high content drug testing and precision medicine
-
批准号:10491072
-
项目类别:
-
资助金额:$59.01万
-
财政年份:2022
-
负责人:MISTY L GOOD
-
依托单位:
Neonatal gut-on-a-chip platform for high content drug testing and precision medicine
-
批准号:10594705
-
项目类别:
-
资助金额:$53.81万
-
财政年份:2022
-
负责人:MISTY L GOOD
-
依托单位:
Neonatal gut-on-a-chip platform for high content drug testing and precision medicine
-
批准号:10674890
-
项目类别:
-
资助金额:$60.36万
-
财政年份:2022
-
负责人:MISTY L GOOD
-
依托单位:
Non-invasive analysis of methylated cell free DNA in necrotizing enterocolitis
-
批准号:10704229
-
项目类别:
-
资助金额:$58.99万
-
财政年份:2021
-
负责人:MISTY L GOOD
-
依托单位:
Non-invasive analysis of methylated cell free DNA in necrotizing enterocolitis
-
批准号:10577705
-
项目类别:
-
资助金额:$64.2万
-
财政年份:2021
-
负责人:MISTY L GOOD
-
依托单位:
Non-invasive analysis of methylated cell free DNA in necrotizing enterocolitis
-
批准号:10316733
-
项目类别:
-
资助金额:$68.7万
-
财政年份:2021
-
负责人:MISTY L GOOD
-
依托单位:
Modulation of the Intestinal Immune Response in Necrotizing Enterocolitis
-
批准号:10543597
-
项目类别:
-
资助金额:$23.33万
-
财政年份:2018
-
负责人:MISTY L GOOD
-
依托单位:
Modulation of the Intestinal Immune Response in Necrotizing Enterocolitis
-
批准号:10468084
-
项目类别:
-
资助金额:$34.57万
-
财政年份:2018
-
负责人:MISTY L GOOD
-
依托单位:
Modulation of the Intestinal Immune Response in Necrotizing Enterocolitis
-
批准号:10001502
-
项目类别:
-
资助金额:$35.44万
-
财政年份:2018
-
负责人:MISTY L GOOD
-
依托单位:
Aryl hydrocarbon receptor signaling in the pathogenesis of necrotizing enterocolitis
-
批准号:9220912
-
项目类别:
-
资助金额:$7.63万
-
财政年份:2017
-
负责人:MISTY L GOOD
-
依托单位:
Novel Anti-Inflammatory Properties of Breast Milk in Necrotizing Enterocolitis
-
批准号:8820360
-
项目类别:
-
资助金额:$14.68万
-
财政年份:2014
-
负责人:MISTY L GOOD
-
依托单位:
Novel Anti-Inflammatory Properties of Breast Milk in Necrotizing Enterocolitis
-
批准号:9391736
-
项目类别:
-
资助金额:$12.8万
-
财政年份:2014
-
负责人:MISTY L GOOD
-
依托单位:
海外基金